Outcomes of patients with Kaposi's sarcomawho start antiretroviral therapy under routine programme conditions in Malawi

Tropical Doctor

Volumn 38, Issue 1, 2008, Pages 5-7

  Makombe, Simon D ^a   Harries, Anthony D ^a,b,c   Yu, Joseph Kwong Leung ^d   Hochgesang, Mindy ^e   Mhango, Eustice ^f   Weigel, Ralf ^f   Pasulani, Olesi ^g   Fitzgerald, Margaret ^g   Schouten, Erik J ^a,h   Libamba, Edwin ^a  

^a MINISTRY OF HEALTH   (Malawi)

^b FAMILY HEALTH INTERNATIONAL   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Mzuzu Central Hospital   (Malawi)

^e Centres for Disease Control   (Malawi)

^f LIGHTHOUSE TRUST   (Malawi)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

^h Management Sciences for Health ^*  (Malawi)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; VINCRISTINE; ANTIRETROVIRUS AGENT;

ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DATA COLLECTION METHOD; DISEASE REGISTRY; HEALTH CARE FACILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALAWI; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PROGNOSIS; SCALE UP; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; MORTALITY; SKIN TUMOR;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTI-RETROVIRAL AGENTS; COHORT STUDIES; HIV INFECTIONS; HUMANS; MALAWI; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 43049178500     PISSN: 00494755     EISSN: 17581133     Source Type: Journal    
DOI: 10.1258/td.2007.060023     Document Type: Article

References (10)

1. Antman K, Chang Y. Kaposi's sarcoma. N Eng J Med 2000;342:1027-1038 (Pubitemid 30180651)
2. Lynen L, Zolfo M, Huyst V, et al. Management of Kaposi's sarcoma in resource-limited settings in the era of HAART. AIDS Rev 2005;7:13-21 (Pubitemid 40667742)
3. Dupont C, Vasseur E, Beauchet A, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. AIDS 2000;14:987-993 (Pubitemid 30336059)
4. Paparizos V, Kyriakis K, Papastamopoulos V, Hadjivassilou M, Stavrianeas N. Response to AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy alone. J Acquir Immune Defic Syndr 2002;30:257-258 (Pubitemid 34664423)
5. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active antiretroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999;13:2105-2111 (Pubitemid 29509588)
6. World Health Organization, UNAIDS. Progress on global access to HIV antiretroviral therapy. A report on '3 by 5' and beyond. Geneva: Switzerland, March 2006
7. Harries AD, Libamba E, Schouten EJ, Mwansambo A, Salaniponi FM, Mpazanje R. Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis. BMJ 2004;329:1163-1166 (Pubitemid 39524779)
8. Libamba E, Makombe S, Harries AD, et al. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes - the case of Malawi. Int J Tuberc Lung Dis 2005;9:1062-1071 (Pubitemid 41433795)
9. World Health Organization. Scaling up Antiretroviral Therapy in Resource-Limited Settings. Treatment Guidelines for a Public Health Approach. Geneva: WHO, 2003
10. Libamba E, Makombe S, Mhango E, et al. Supervision, monitoring and evaluation of nationwide scale up of antiretroviral therapy in Malawi. Bull World Health Organ 2006;84:320-326